

**Spark NIR™ 685 anti-human CD62L**

**Catalog # / Size:** 2124305 / 25 tests  
2124310 / 100 tests

**Clone:** DREG-56

**Isotype:** Mouse IgG1, κ

**Immunogen:** Concentrated supernatant from PMA-activated human peripheral blood leukocytes


**Reactivity:** Human, Other

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Spark NIR™ 685 under optimal conditions.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)

**Workshop Number:** V S056

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stained with CD62L (clone DREG-56) Spark NIR™ 685 (filled histogram) or mouse IgG1, κ Spark NIR™ 685 isotype control (open histogram).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

\* Spark NIR™ 685 has a maximum excitation of 665 nm and a maximum emission of 685 nm.

**Application Notes:** Additional reported applications (for the relevant formats) include: Western blotting<sup>2,3,9</sup> and *in vitro* blocking of lymphocytes binding to high endothelial venules (HEV)<sup>2</sup>. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 304853-304858).

- Application References:**
- Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  - Kishimoto TK, et al. 1990. *Proc. Natl. Acad. Sci. USA* 87:2244. (WB, Block)
  - Jutila M, et al. 2002. *J. Immunol.* 169:1768. (WB)
  - Tamassia N, et al. 2008. *J. Immunol.* 181:6563. (FC) [PubMed](#)
  - Kmieciak M, et al. 2009. *J. Transl. Med.* 7:89. (FC) [PubMed](#)
  - Thakral D, et al. 2008. *J. Immunol.* 180:7431. (FC) [PubMed](#)
  - Charles N, et al. 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
  - Yoshino N, et al. 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
  - Koenig JM, et al. 1996. *Pediatr. Res.* 39:616. (WB)
  - Shi C, et al. 2011. *J. Immunol.* 187:5293. (FC) [PubMed](#)
  - Burges M, et al. 2013. *Clin Cancer Res.* 19:5675. [PubMed](#)
  - Cash JL, et al. 2013. *EMBO Rep.* 14:999. (FC) [PubMed](#)

**Description:** CD62L is a 74-95 kD single chain type I glycoprotein referred to as L-selectin or LECAM-1. It is expressed on most peripheral blood B cells, subsets of T and NK cells, monocytes, granulocytes, and certain hematopoietic malignant cells. CD62L binds to carbohydrates present on certain glycoforms of CD34, glycam-1, and MAdCAM-1 and with a low affinity to anionic oligosaccharide sequences related to sialylated Lewis X (sLex, CD15s) through its C-type lectin domain. CD62L is important for the homing of naïve lymphocytes to high endothelial venules in peripheral lymph nodes and Peyer's patches. It also plays a role in leukocyte rolling on activated endothelial cells.

**Antigen** 1. Kishimoto T, *et al.* 1990. *P. Natl. Acad. Sci. USA* 87:2244.  
**References:** 2. Kishimoto T, *et al.* 1991. *Blood* 78:805.